Sandeep Kumar

So the first question is on like what is the current status of denosumab biosimilar in the U.S.?

Okay. So then my second question is on the EU region. So on the -- following the approval of [0 11:13], so are there any specific targets like region markets where the launch is being prioritized or is like full EU availability expected simultaneously?

Yes, Prolia biosimilar. So is there any specific regions we are targeting or like…